GlaxoSmithKline acquires remaining stake in Glycovaxyn for $190m
Since 2012, GSK owned a minority stake in Glycovaxyn, which has developed a biological conjugation platform technology that could help in the development of new prophylactic and therapeutic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.